HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

Description

HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.

Conditions

Huntington's Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

Condition
Huntington's Disease
Intervention / Treatment

-

Contacts and Locations

Englewood

Cenexel, Englewood, Colorado, United States,

Washington

Georgetown University, Washington, District of Columbia, United States, 20057

Baltimore

John Hopkins University, Baltimore, Maryland, United States, 21287

Winston-Salem

Wake Forest University, Winston-Salem, North Carolina, United States, 27109

Nashville

Vanderbilt University Medical Center, Nashville, Tennessee, United States, 37212

Houston

University of Texas Health Science Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age (18-75 years controls, early/late premanifest HD and incomplete penetrance HD, 21-75 years early/moderate/advanced manifest HD, ≥11 years juvenile HD)
  • * Enroll HD participant
  • * Capable of consenting or have a legal representative (parent/guardian for juveniles)
  • * Capable of complying with study procedures
  • * All participants other than family and community controls must have had a genetic test for HD
  • * Drug trial within 30 days of any sampling visit
  • * Changes in medication (antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD within 30 days)
  • * Antiplatelet or anticoagulant therapy within 14 days
  • * Significant comorbidity
  • * Needle phobia, headache, spinal surgery / deformity
  • * Clotting or bruising disorder
  • * Screening blood test abnormalities \>10% outside normal range
  • * Drug / alcohol abuse
  • * Positive urine pregnancy test at any screening or sampling visit for females of childbearing potential
  • * Predictable non compliance or unwillingness
  • * Serious adverse event related to HDClarity study procedures or any lumbar puncture procedure performed for any reason in the previous 30 days

Ages Eligible for Study

11 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University College, London,

Edward J Wild, MA, MB BChir, MRCP, PhD, PRINCIPAL_INVESTIGATOR, University College, London

Study Record Dates

2025-05-01